NASDAQ:KZR - Kezar Life Sciences Stock Price, Forecast & News

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences Inc (NASDAQ:KZR) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.03. View Kezar Life Sciences' Earnings History.

Kezar Life Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Kezar Life Sciences.

3 brokers have issued 12-month price targets for Kezar Life Sciences' shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate Kezar Life Sciences' stock price to reach $15.00 in the next year. This suggests a possible upside of 172.2% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.

Headlines about KZR stock have trended somewhat positive on Wednesday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kezar Life Sciences earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the near term. View News Stories for Kezar Life Sciences.

Some companies that are related to Kezar Life Sciences include Arcus Biosciences (RCUS), DiaMedica Therapeutics (DMCAF), Homology Medicines (FIXX), Endonovo Therapeutics (ENDV), ImmunoGen (IMGN), ANI Pharmaceuticals (ANIP), Frequency Therapeutics (FREQ), Eagle Pharmaceuticals (EGRX), Phoenix Tree (IMAB), Omeros (OMER), G1 Therapeutics (GTHX), Basilea Pharmaceutica (BPMUF), Cara Therapeutics (CARA), Flexion Therapeutics (FLXN) and Akero Therapeutics (AKRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Opko Health (OPK), Aptinyx (APTX), Ovid Therapeutics (OVID), vTv Therapeutics (VTVT), Kadmon (KDMN), ADMA Biologics (ADMA), Blueprint Medicines (BPMC), Codexis (CDXS), Crispr Therapeutics (CRSP) and Exelixis (EXEL).

(KZR) raised $70 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

Kezar Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Victory Capital Management Inc. (6.66%), Victory Capital Management Inc. (2.59%), State Street Corp (1.19%), Geode Capital Management LLC (0.37%) and Acadian Asset Management LLC (0.64%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment and Vassiliki Economides. View Institutional Ownership Trends for Kezar Life Sciences.

KZR stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, Alambic Investment Management L.P., Goldman Sachs Group Inc., Renaissance Technologies LLC and State Street Corp. View Insider Buying and Selling for Kezar Life Sciences.

KZR stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BVF Inc. IL, Acadian Asset Management LLC, FMR LLC, Victory Capital Management Inc., Private Advisors LLC, Bank of Montreal Can and Barclays PLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment and Vassiliki Economides. View Insider Buying and Selling for Kezar Life Sciences.

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KZR stock can currently be purchased for approximately $5.51.

Kezar Life Sciences has a market capitalization of $194.28 million. The company earns $-23,170,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.View Additional Information About Kezar Life Sciences.

The official website for Kezar Life Sciences is http://www.kezarlifesciences.com/.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]